SCHENECTADY, N.Y., Jan. 12 /PRNewswire/ -- CardioMag has received official certification from the State Food and Drug Administration (SFDA) of the People's Republic of China, that its product -- a Magnetocardiograph (MCG) -- has been inspected by the SFDA and is permitted to be sold commercially in the Chinese medical market. The device, which non-invasively detects the magnetic field generated by a person's electric activity in the heart, is already installed at the TEDA International Cardiovascular Hospital located in Tianjin, China.
Carl H. Rosner, President and CEO stated: "We are very pleased with this vote of confidence by the Chinese Government Agency, because receipt of this certification will allow CardioMag to enter the very large Chinese hospital marketplace for both research and clinical patient applications. It is estimated that there are about 20,000 hospitals in all of China, of which up to 2,000 are potential customers."
He further noted that it appears, Chinese patients in particular like the fact that an MCG procedure takes less than ten minutes to perform, is risk-free, and does not require injections or exposes the patient to X-ray radiation. With the capability to generate a thousand field mapping images per heartbeat, CardioMag's MCG system provides unprecedented insight into the human heart at work.
Safe Harbor Statement: The statements presented in this press release which are not historical facts are forward looking statements which involve various important assumptions, risks, uncertainties and other factors set forth here, including but not limited to, market acceptance by healthcare providers, obtaining FDA approval for future claims, insurance reimbursement policies, and growth of the market.
CardioMag Imaging, Inc.
CONTACT: Carl H. Rosner, Executive Chairman of CardioMag Imaging, Inc.,+1-518-381-1000, ext. 63; or Eric Burns, +011-44-1943-833990, or LisaBaderoon, +011-44-207-4665000, both of Buchanan Communications - U.K., forCardioMag Imaging, Inc.